This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As formulators, we are often able to directly impact the amount of drug absorbed through formulation optimization and improve exposure. However, the chances of improving the exposure profile of a drug that is highly cleared by formulation modification are limited. Please check your email to download the Whitepaper.
The presentation reflected the findings from a recent webinar ASBM held on this subject with GaBI Journal. Among the factors identified in the webinar were the ability for physicians to choose freely between multiple products- innovators and biosimilars- when prescribing. Read the GaBI Journal report of the webinar here.
The traditional model of drugdevelopment and healthcare delivery is undergoing a seismic shift, with patient engagement emerging as a critical factor in achieving better health outcomes and driving innovation. This change is further driven by major regulatory bodies emphasizing Patient-Focused DrugDevelopment (PFDD).
Acting as a go-between for pharma and physicians, medical science liaisons (MSLs) are responsible for communicating necessary information about new medicines to healthcare professionals and key opinion leaders (KOLs). These webinar and group meeting systems are an evolving sector. Best of both worlds.
A vitally important assay used across various stages of drugdevelopment and manufacturing, container closure integrity testing (CCIT) involves evaluating packaging systems to determine their ability to protect the stability and sterility of pharmaceutical products. Free Webinar. Please check your email to download the Webinar.
Webinars & Virtual Conferences HCPs value expert insights and peer discussions. Hosting webinars with leading researchers, KOLs (Key Opinion Leaders), and medical professionals enhances credibility. Behind-the-scenes research lab videos showcasing drugdevelopment. Medication trackers & digital health guides.
Key Opinion Leaders play a critical role in the life sciences industry – pharmaceutical companies often engage them during clinical trials and drug commercialization. However, given the current regulatory approval challenges, many pharma companies seek to collaborate with KOLs medical throughout the entire drugdevelopment cycle.
With machine learning and big data analytics, companies can now predict market trends, enhance drugdevelopment, and create hyper-personalized campaigns. A great example is how Merck and AstraZeneca use AI-driven content to engage physicians via targeted LinkedIn campaigns, automated email sequences, and interactive medical webinars.
The patient community defeated Congressional attempts to cut Medicaid funding and supported our constituents in the unwinding of COVID-19-era increased enrollment. We also offered webinars highlighting key expertise within membership, including the pharmacy community, medical device and technology sector, and health care payers.
This method not only prioritizes the participant’s comprehension but also aligns with best practices in health communication that suggests a focused approach can significantly enhance understanding and retention of important information. The importance of using plain language in health communications is well-documented in literature.
Several drugdevelopment trends are driving injectables demand. This includes the rising number of biologic drugs on the market, which are mostly administered parenterally. This on-demand webinar discusses the importance of a patient-appropriate BL & GF profile. Please check your email to download the Webinar.
Unlike other industries, pharma marketers must understand drugdevelopment, regulatory requirements, and clinical trial data to craft effective messaging. Combining HCP webinars, digital advertising, and interactive medical content enhances outreach effectiveness. What role does omnichannel marketing play in pharma?
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content